Revolutionary advances in biology raise expectations for patients and families waiting for cures. Unfortunately, the path from breakthroughs to drugs is torturous and unpredictable. Looking at two prominent examples, RNA interference and genome editing, we can extract some common themes and key lessons applicable to future discoveries.
About Our Speaker
David Bumcrot, PhD, is Chief Scientific Officer and Senior Vice President of Research at CAMP4 Therapeutics, where he oversees the Biology, Data Science and Discovery teams.
Prior to joining CAMP4, Dr. Bumcrot led groups at innovative biotech companies advancing novel technologies towards clinical development. He was one of the first employees at Alnylam pharmaceuticals where he spent ten years working to make RNA interference-based drugs a reality for multiple indications, including key contributions to a first-in-class systemically administered siRNA therapeutic tested in an oncology clinical trial. Dr. Bumcrot then moved on to Editas Medicine where his team established the company’s initial therapeutic programs utilizing groundbreaking CRISPR technology.
Dr. Bumcrot received his Bachelor of Science degree from Cornell University and a PhD in molecular biology from the University of Pennsylvania. He completed a post-doctoral fellowship at Harvard University.
